Skip to main content

Transverse Myelitis

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Q Therapeutics
Q TherapeuticsUT - Salt Lake City
1 program
Q-CellsPHASE_1_21 trial
Active Trials
NCT03887273Unknown9Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Q TherapeuticsQ-Cells

Clinical Trials (1)

Total enrollment: 9 patients across 1 trials

Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis

Start: Sep 2022Est. completion: Dec 20249 patients
Phase 1/2Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.